How has AbbVie's stock performed recently?

AbbVie's stock rose 10.83% in the past month, 23.60% over one year, and 83.11% over three years.

Why are these approvals important for AbbVie?

The new approvals help AbbVie diversify its revenue streams and offset declining Humira sales due to biosimilar competition.

AbbVie Gains Regulatory Approvals for Rare Cancer and Migraine Drugs

AbbVie received FDA approval for DECNUPAZ to treat a rare blood cancer, along with European approvals for migraine drug AQUIPTA and new VENCLYXTO combinations. The news comes as the stock rose 10.83% over the past month.

June 6, 2026

2 min read

Source: Simply Wall St.

Key Numbers

1 month return

10.83%

1 year return

23.60%

3 year return

83.11%

AbbVie (ABBV) has secured a series of regulatory approvals, including FDA clearance for DECNUPAZ to treat a rare blood cancer, and European approvals for migraine drug AQUIPTA and new combinations of VENCLYXTO.

Regulatory Details

DECNUPAZ: Approved by the FDA for a rare myeloproliferative neoplasm.
AQUIPTA: Received European approval for migraine treatment.
VENCLYXTO: New combination regimens approved in Europe.

Company Stance

AbbVie stated its commitment to expanding its therapeutic portfolio in oncology and neurology. The approvals are seen as strategic moves to offset declining Humira revenues due to biosimilar competition.

Context

The approvals follow strong stock performance, with a 1-month return of 10.83%, 1-year return of 23.60%, and 3-year return of 83.11%. AbbVie continues to diversify its revenue streams.

Potential Financial Impact

The new approvals are expected to boost AbbVie's future revenues, though the company has not issued specific financial guidance for these products. Competition remains intense in both the migraine and blood cancer markets.

Frequently Asked Questions

AbbVie received FDA approval for DECNUPAZ to treat a rare blood cancer, and European approvals for migraine drug AQUIPTA and new VENCLYXTO combinations.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.